Progress of programmed death 1 and its ligand in treatment of gastric cancer

Immunotherapy targeted on programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) has been approved by US Food and Drug Administration (FDA) for the treatment of solid tumors such as melanoma, non-small cell lung cancer and renal cell carcinoma. Preliminary study on the gastrointestinal solid tumor has been carried out, which has shown favorable efficacies and promising application prospect. However, some disadvantages have appeared. This article reviews the progress of immunotherapy for gastric adenocarcinoma. Key words: Stomach neoplasms; Immunotherapy; Programmed death 1; Programmed death 1 ligand